In this installment of the “How I treat ...” series in Blood, the authors use four case studies to describe their approach to treating adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL). Recent studies using pediatric regimens in this population (up to age 39) has shown improvements in event-free survival rates ranging from 60% to 70%. The authors discuss the use of prognostic markers such as minimal residual disease (MRD) and note that high-risk patients with persistent MRD following early consolidation therapy should be referred for transplant consultation. The authors discuss the biology, pharmacology, and psychosocial aspects of AYA patients, and note that a holistic approach, incorporating a multidisciplinary team, is key to successful treatment.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: ALL in Older Adolescents and Young Adults
Jul 2015